Pharmaceuticals, Biotechnology and Life Sciences
Boehringer Ingelheim has reported new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.
Alexion Pharmaceuticals has announced big changes to its executive leadership team. Brian Goff is joining Alexion as Chief Commercial Officer, effective June 1, 2017.
Genomic Vision, a company specialized in the development of diagnostic tests (IVD) for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), have entered into a technological collaboration with AstraZeneca in the field of targeting DNA damage response (DDR) for novel anti-cancer treatments strategy.
Zealand Pharma has reported positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes.
Biocartis Group, an innovative molecular diagnostics company, has launched of the Idylla NRAS Mutation Test.
SkinBioTherapeutics, a life science company focused on skin health, has agreed an eight month extension to its research contract with the University of Manchester to June 2018.
Oxford BioDynamics, a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has entered into a development agreement with two pharmaceutical companies, that are collaborating on an anti PD-L1 therapy.
AstraZeneca has reported top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that compared the effect of once-weekly Bydureon (exenatide extended-release) versus placebo, when added to usual type-2 diabetes care, on the risk of MACE, a composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes (T2D) at a wide range of CV risk.
Novartis’ head-to-head FLAME study suggest that inhaled corticosteroids (ICS) may not be needed in some chronic obstructive pulmonary disease (COPD) patients with high blood eosinophil (a type of white blood cell) counts.
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).